JP Morgan Chase
OCEA

JP Morgan Chase’s Ocean Biomedical, Inc. Common Stock OCEA Stock Holding History

JP Morgan Chase’s Portfolio OCEA Stock Details OCEA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-233
Closed -$12 – 7850
2025
Q1 		$12 Sell
233
-3
-1% -$1 ﹤0.01% 7179
2024
Q4 		$131 Buy
236
+27
+13% +$21 ﹤0.01% 6971
2024
Q3 		$205 Sell
209
-1,546
-88% -$1.66K ﹤0.01% 6900
2024
Q2 		$2.14K Sell
1,755
-7,728
-81% -$13.2K ﹤0.01% 6518
2024
Q1 		$35.9K Buy
9,483
+741
+8% +$1.39K ﹤0.01% 6053
2023
Q4 		$5.77K Buy
8,742
+3,116
+55% +$4.28K ﹤0.01% 6531
2023
Q3 		$21.9K Sell
5,626
-1,290
-19% -$5.93K ﹤0.01% 6048
2023
Q2 		$41.6K Buy
+6,916
New +$40.5K ﹤0.01% 5760

Other funds holding OCEA

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

JP Morgan Chase's OCEA Position: Q2 2025 in Review

JP Morgan Chase sold out of Ocean Biomedical, Inc. Common Stock (OCEA) in Q2 2025, closing a stake of 233 shares — an estimated $12 sold.

JP Morgan Chase first reported a position in OCEA in Q2 2023 and held it in 8 quarters. The position peaked at $41.6K in Q2 2023. 7 funds tracked by Wall St. Rank hold OCEA as of Q2 2025.

  • JP Morgan Chase reported no remaining Ocean Biomedical, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 233 Ocean Biomedical, Inc. Common Stock shares in Q2 2025, an estimated $12.
  • JP Morgan Chase first reported a position in Ocean Biomedical, Inc. Common Stock in Q2 2023 and held it in 8 quarters.
  • JP Morgan Chase's Ocean Biomedical, Inc. Common Stock position peaked at $41.6K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Ocean Biomedical, Inc. Common Stock as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.